On Monday, Nov. 17th at 6:30 pm EST, Richard Jefferys, Basic Science, Vaccines and Cure Project director at the Treatment Action Group (TAG), delivers the 29th annual Jonathan Lax Memorial Lecture at The Wistar Institute in recognition of his outstanding contributions to HIV research, education and advocacy.
TAG signed onto this letter sponsored by the HIV Legal Network to Canadian Prime Minister Mark Carney about the importance of strong investments in health and community systems as they reinforce global health security, which in turn keeps everyone safe.
In March 2025, the National Institute of Allergy and Infectious Diseases (NIAID) began soliciting comments on the future of the four Division of AIDS (DAIDS)-sponsored HIV clinical research networks: ACTG, IMPAACT, HPTN, and HVTN.
TAG’s annual Research in Action Awards is our most anticipated night of the year.
Treatment Action Group and ANEA Coalition strongly condemn the House Labor, Health and Human Services proposed $2 billion in federal cuts to domestic HIV programs, including plans that would dismantle the CDC’s Division of HIV Prevention and slash $535 million from the Ryan White HIV/AIDS Program.
A global coalition reacted to two deals announced today to make long acting lenacapavir (LEN-LA), a 6 monthly HIV PrEP (pre-exposure prophylaxis) injection that provides virtually 100% protection against HIV infection, at $40 per person per year in 2027.
On Sept. 3 20+ organizations — including TAG — signed this Infectious Diseases Society of America’s (IDSA) joint statement calling for the resignation of Sec. Robert F. Kennedy Jr. The letter outlines the many ways Kennedy’s “agenda” is meant to undermine science and public health.
This Hepatitis C virus (HCV) storyboard describes the experience of Sibusiso Dlamini in Tsawne, South Africa. Sibusiso is a young man who began using substances for leisure in high school, and later in life switched to injecting substances for a stronger high.
The World Health Organization (WHO) guidelines for diagnosing TB have evolved along with available technologies and tools that are increasingly accurate, simple, and efficient at detecting TB and resistance to a wider range of TB drugs.
I’m proud to share with you TAG’s 2024 Annual Report. Last year already seems long ago with all the attacks on research and health care, domestic and international, which are currently taking place under the new administration...